Evidence map›Paper›PMID 42871077›Full record

ArticleFrontiers in cardiovascular medicine2026

Serum free eicosapentaenoic acid-to-arachidonic acid ratio and long-term risk of major adverse cardiovascular events in patients with coronary artery disease.

Changguo Ou, Wenli Wang, Dongliang Liang, Jiangxiong Wen, Zhiwen Xu, Yuli Huang, Jianqiu Liang, Jiandi Wu

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Changguo OuThe First Clinical Medical College of Guangdong Medical University, Zhanjiang, China.
Wenli WangThe First Clinical Medical College of Guangdong Medical University, Zhanjiang, China.
Dongliang LiangDepartment of Cardiology, Foshan Second People's Hospital, Foshan, China.
Jiangxiong WenDepartment of Cardiology, Foshan Second People's Hospital, Foshan, China.
Zhiwen XuDepartment of Cardiology, Foshan Second People's Hospital, Foshan, China.
Yuli HuangDepartment of Cardiology, Eighth Affiliated Hospital of Southern Medical University, Foshan, China.
Jianqiu LiangDepartment of Cardiology, Foshan Second People's Hospital, Foshan, China.
Jiandi WuThe First Clinical Medical College of Guangdong Medical University, Zhanjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio reflects the balance between n-3 and n-6 polyunsaturated fatty acids. We examined the association between the serum free (non-esterified) EPA/AA ratio and long-term major adverse cardiovascular events (MACE) in patients with angiographically confirmed coronary artery disease (CAD). Methods: This single-center retrospective cohort study included 308 patients with CAD. Serum free fatty acids were quantified by LC-MS/MS, and the free EPA/AA ratio was evaluated as the primary fatty-acid biomarker. Cox proportional hazards models were used to estimate hazard ratios (HRs), and principal component analysis (PCA) was used to explore fatty-acid patterns. Results: During a median follow-up of 48.7 months, 201 first MACE events occurred. In the fully adjusted primary analysis, each 1-SD increase in the free EPA/AA ratio was associated with a lower risk of MACE (HR = 0.82, 95% CI 0.70-0.96, Conclusions: A higher serum free EPA/AA ratio was associated with a lower risk of MACE in the primary multivariable analysis, but the association was attenuated in additional sensitivity analyses. These findings should be interpreted cautiously and require validation in independent cohorts.

Indexed as

coronary artery diseasefree EPA/AA ratiomajor adverse cardiovascular eventsnon-esterified fatty acidsprognosis

Identifiers

PMID42871077
PMCPMC13658503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.